| Drug Name |
Eribulin mesylate |
| Drug ID |
BADD_D00799 |
| Description |
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439]. |
| Indications and Usage |
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX41 |
| DrugBank ID |
DB08871
|
| KEGG ID |
D08914
|
| MeSH ID |
C490954
|
| PubChem ID |
17755248
|
| TTD Drug ID |
D0XQ5X
|
| NDC Product Code |
33656-0018; 61662-0019; 11071-891; 71796-044; 62856-389; 11071-892; 66499-0074; 13612-0022; 58272-208; 43624-002 |
| UNII |
AV9U0660CW
|
| Synonyms |
eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate) |
